A linear regression analysis suggested that there was only a marginal effect of the proportion of EZH2-expressing tumor cells on the crude disease-free survival of young patients, with borderline significance (F(1,66) = 3.95, p = 0.05, with an R2 = 0.06 and a regression coefficient of −0.4); thus, the one percent increase in the proportion of EZH2-expressing cells might be related to a 0.4-month decrease in the predicted DFS with great scatter in the data. This evidence concerns the gene EZH2 and neoplasm.